InvestWiser

SenzaGen AB

SENZANasdaq StockholmHealthcareMarket value 147 m SEK
4.51SEK +1.1%
last day · Price as of 18 November 2026

The answer first

Does SenzaGen beat the market?

No, SenzaGen has not beaten the market over the last year.

SenzaGen−27.7%Stockholm (OMXSGI)+17.6%
  • The ranking · Quality, value and trend combined

    Better than 35% of Nordic stocks

    • Quality78
    • Value33
    • Trend21

    No. 93 of 195 in healthcare

Max for seven days

Follow SenzaGen with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on SenzaGen

From today, at a price of 4.51 SEK. Write why you follow SenzaGen, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about SenzaGen

Your first answer is free, no account needed.

Do you own SenzaGen, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with SenzaGen and a few more. Free, no card.

Past year against the exchange and Super Stock
SenzaGen−27.7%Stockholm (OMXSGI)+17.6%Super Stock+44.6%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • SenzaGen has fallen 27.7% over the past year, including dividends.
  • Overall, SenzaGen ranks better than 35% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 77.2%. The price is 93.5% below its peak now.

What do analysts think of SenzaGen?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

35

Quality, value and trend together. Better than 35% of Nordic stocks.

No. 93 of 195 in healthcare

Quality78
The company · Fundamentals: the accounts

High A solid company: it earns well on its money and has healthy finances.

No. 58 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.33
  • Asset turnoverSales divided by everything the company owns0.49
  • Return on equityProfit divided by equity−7.9%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value33
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 69 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity1.6
  • P/SPrice divided by sales2.3
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend21
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 123 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−12.6%
  • 6 months−17.1%
  • 9 months−21.7%
  • 12 months−27.7%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−3.0%
3 years, per year
−15.2%
5 years, per year
−18.4%
Year to date
−25.8%
Largest fall, 3 years
−77.2%
From a peak to the bottom
From the peak now
−93.5%
How far the price is from the peak
Volatility, 1 year
38.3%
How much the price swings over a year
Beta, 1 year
0.49
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own SenzaGen

One fund we follow owns SenzaGen. The share is how much of the fund the stock makes up.

  • Sweden1

From the funds' latest known holdings.

About SenzaGen

SenzaGen AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 34 employees.

SenzaGen AB (publ) provides non-animal tests for assessing allergenicity. The company offers GARD skin OECD 442E, GARD skin dose-response, GARD skin medical device; and GARD air, a respiratory sensitization assessment. It also provides biological evaluation, in vitro biocompatibility testing, cytotoxicity, irritation, and skin sensitization medical device services; advisory services for medical devices; and substance based medical devices.

See the full analysis of SenzaGen.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market